Is Scinai Immunotherapeutics Ltd. (SCNI) a Buy, Sell, or Hold?
NASDAQ : SCNI
Scinai Immunotherapeutics Ltd.
$0.244 USD
$0.0 (-0.53%)
- Volume
- 21.62K
- Average Volume
- 417.92K
- Market Capitalization
- $320.95K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.97
- Year Low
- $0.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.35
Company Overview
NASDAQ
Amir Reichman
Biotechnology
Healthcare
SCNI
45
IL
USD
Liquidity Metrics
0.30
1.35
1.35
1.16
0.00
Sales & Valuation
$1.31M
0.23
0.00
-0.05
-6824.20
Profitability
-$3.6
-$8.31M
-188.87%
-338.68%
-29.84%
-15.20%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
3/5
0 Analysts
%
Financial Health Scores
-11.28
4/9
$929.01K
$17.59M
$5.83M
-$9.22M
Key Metrics (TTM)
$704.66K
0.50
-0.09
1.35
-29.84%
-53.23%
-1150981.11%
-2002.13%
-24 days
Company Executives
| Name | Title |
|---|---|
| Uri Ben-Or | Chief Financial Officer |
| Elad Mark | Chief Operating Officer |
| Naama Adi Hen | Head of Quality Asurance |
| Gal Ron | Head of HR |
| Merav Kamensky | Head of Quality Control & GMP Analytics |
| Amir Reichman | Chief Executive Officer & Director |
| Tehila Sonnenfeld | Head of Manufacturing |
Poll Results
No votes yet today — be the first to share your view!
About Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Stock
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in Septemb ... er 2023. Its corporate headquarters are situated in Jerusalem, Israel.
2026-08-10 06:34:00
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
2026-06-10 07:55:00
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
2026-05-20 07:00:00
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd.
2026-05-15 08:05:00
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands.
Frequently Asked Questions
-
What is the current Scinai Immunotherapeutics Ltd. (SCNI) stock price?
-
Scinai Immunotherapeutics Ltd.(NASDAQ:SCNI) stock price is $0.244 in the last trading session. During the trading session, SCNI stock reached the peak price of $1.97 while $0.215 was the lowest point it dropped to. The percentage change in SCNI stock occurred in the recent session was --0.53% while the dollar amount for the price change in SCNI stock was -$0.0.
-
SCNI's industry and sector of operation?
-
The NASDAQ listed SCNI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SCNI?
-
Uri Ben-Or | Chief Financial Officer
Elad Mark | Chief Operating Officer
Naama Adi Hen | Head of Quality Asurance
Gal Ron | Head of HR
Merav Kamensky | Head of Quality Control & GMP Analytics -
How many employees does SCNI have?
-
Number of SCNI employees currently stands at 45. SCNI operates from Jerusalem BioPark Building, Jerusalem, JM 9112001, IL.
-
Link for SCNI official website?
-
Official Website of SCNI is: https://www.scinai.com
-
How do I contact SCNI?
-
SCNI could be contacted at phone #972 8 930 2529 and can also be accessed through its website. SCNI operates from Jerusalem BioPark Building, Jerusalem, JM 9112001, IL.
-
How many shares of SCNI are traded daily?
-
The average number of SCNI shares traded daily for last 3 months was 417.92K.
-
What is the market cap of SCNI currently?
-
The market value of SCNI currently stands at $320.95K with its latest stock price at $0.244